GSK axes Blenrep combo studies with SpringWorks` Ogsiveo
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
“ Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation “ “ Additional data and analyses from Phase 3 DeFi trial of OGSIVEO®...
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
“ Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter “ “ Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid...
“ Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation ““ Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid...
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Initiates Rolling Submission of NDA to the FDA for Mirdametinib
SpringWorks Therapeutics Announces EMA Validation for MAA of Nirogacestat
SpringWorks Announces EMA Validation for MAA of Nirogacestat